Inflammatory bone loss: pathogenesis and therapeutic intervention

被引:0
作者
Kurt Redlich
Josef S. Smolen
机构
[1] Medical University of Vienna,Division of Rheumatology, Department of Medicine 3
来源
Nature Reviews Drug Discovery | 2012年 / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Bone homeostasis is dependent on the concerted actions of bone-building osteoblasts and bone-degrading osteoclasts — a process called bone remodelling.Two of the major factors that induce osteoblast differentiation and activation are: the signalling mediated by bone morphogenetic proteins via runt-related transcription factor 2; and the WNT–Frizzled–β-catenin pathway. Conversely, Dickkopf-related protein 1 (DKK1) and sclerostin inhibit osteoblast activation.Major molecules involved in osteoclast differentiation and activation include macrophage colony-stimulating factor and receptor activator of nuclear factor-κB (RANK) as well as its ligand (RANKL).Inflammation is associated with the overproduction of various cytokines, such as tumour necrosis factor, interleukin-1 (IL-1), IL-6 or IL-17. Their upregulation in the course of inflammation leads to excessive bone degradation mainly due to hyperactivation of osteoclasts, although some cytokines can also impair osteoblast function.Many diseases lead to inflammatory bone loss, including inflammatory bowel disease, chronic obstructive lung disease, cystic fibrosis, periodontitis, rheumatoid arthritis and other inflammatory diseases.Inflammatory bone loss is always systemic, and in some diseases — such as rheumatoid arthritis or periodontitis — it can also involve local bone.Therapies interfering with inflammation also affect systemic inflammatory bone loss, primarily by reducing the effects of cytokines on osteoclast activation; however, many of these treatments will not fully control inflammation. Owing to this ongoing inflammatory activity (even at low levels), bone loss will continue to accrue and therefore also requires specific targeting of bone cells.Bisphosphonates and denosumab are among the bone-targeting therapies that have been shown to be effective in treating inflammatory bone loss, but it is assumed that blockers of DKK1 and sclerostin — which are upregulated by cytokines and inhibit osteoblast repair mechanisms — are also likely to be effective.
引用
收藏
页码:234 / 250
页数:16
相关论文
共 516 条
[91]  
Manolagas SC(2004)Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis Am. J. Pathol. 164 543-211
[92]  
Hay E(1996)Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma Gastroenterology 111 1263-28
[93]  
Lemonnier J(1993)A longitudinal study of the relationship between periodontal disease and bone mineral density in community-dwelling older adults Atherosclerosis 103 205-998
[94]  
Fromigue O(2002)Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis Compend. Contin. Educ. Dent. 23 21-R67
[95]  
Guenou H(2006)Colitis causes bone loss in rats through suppression of bone formation Am. J. Pathol. 169 987-517
[96]  
Marie PJ(2000)Dental infections and coronary atherosclerosis J. Clin. Invest. 106 R59-186
[97]  
Bradford PG(2009)Oral osteoporosis: is there an association between periodontitis and osteoporosis? Annu. Rev. Immunol. 27 485-168
[98]  
Gerace KV(2012)B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease Inflamm. Bowel Dis. 18 180-1652
[99]  
Roland RL(2006)Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection Arthritis Rheum. 54 158-503
[100]  
Chrzan BG(1991)IL-17 and Th17 cells Blood 77 1627-1450